Stocks · News reference

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Jul 31, 2026, 5:32 PMVandana Singh

Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 31, 2026, 5:32 PM
Checked: Jul 31, 2026, 5:32 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 3, 2026, 12:55 PMBenzinga Newsdesk
Tiziana Life Sciences shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $7 price target.
TLSA
BenzingaSep 3, 2026, 12:10 PMAvi Kapoor
This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).
COP NRSN OXY SM TLSA
BenzingaSep 3, 2026, 10:08 AMBenzinga Newsdesk
BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7
BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.
TLSA
BenzingaAug 24, 2026, 11:04 AMBenzinga Newsdesk
Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026
TLSA